ACCUSIGN MTD, BIOSIGN MTD

K991080 · Princeton BioMeditech Corp. · DJR · Apr 15, 1999 · Clinical Toxicology

Device Facts

• Record ID: K991080
• Device Name: ACCUSIGN MTD, BIOSIGN MTD
• Applicant: Princeton BioMeditech Corp.
• Product Code: DJR · Clinical Toxicology
• Decision Date: Apr 15, 1999
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 862.3620
• Device Class: Class 2

Intended Use

Immunoassay for the qualitative detection of methadone in human urine to assist in screening of drug of abuse samples and/or diagnosis of clinical symptoms associated with the use of drug.

Device Story

AccuSign® MTD is an immunoassay for qualitative detection of methadone in human urine. Used for screening drug of abuse samples or diagnosing clinical symptoms of drug use. Operated by healthcare professionals in clinical settings. Device provides visual qualitative results to assist clinical decision-making regarding drug exposure.

Clinical Evidence

No clinical data provided in the document.

Technological Characteristics

Immunoassay-based diagnostic test for urine samples. Form factor is a test device for qualitative detection. Professional use only.

Indications for Use

Indicated for the qualitative detection of methadone in human urine to assist in screening for drugs of abuse and/or diagnosis of clinical symptoms associated with drug use. For professional, prescription use.

Regulatory Classification

Identification

A methadone test system is a device intended to measure methadone, an addictive narcotic pain-relieving drug, in serum and urine. Measurements obtained by this device are used in the diagnosis and treatment of methadone use or overdose and to determine compliance with regulations in methadone maintenance treatment.

Special Controls

*Classification.* Class II (special controls). A methadone test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its body and wing. The eagle is enclosed within a circle that contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.

Public Health Service

APR 1 5 1999

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Jemo Kang, Ph.D. President Princeton BioMeditech Corporation 4242 U.S. Route 1 Monmouth Junction, NJ 08852-1905

Re: K991080 Trade Name: AccuSign® MTD Regulatory Class: II Product Code: DJR Dated: March 22, 1999 Received: March 26, 1999

Dear Dr. Kang:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number [phone] or at [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Autman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

| Page | of |
|------|----|
|------|----|

| 510(k) Number (if known): | K991080 |
|---------------------------|---------------------------|
| Device Name: | AccuSign ^® MTD |

Indications For Use:

:

Immunoassay for the qualitative detection of methadone in human urine to assist in screening of drug of abuse samples and/or diagnosis of clinical symptoms associated with the use of drug.

Je cen Cooper

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K991086

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH Office of Device Evaluation (ODE)

Professional Use:_X Prescription Use:_X r 21 CFR 801.109)

OR

Over The Counter Use: ________________________________________________________________________________________________________________________________________________________

(Optional Format 1-2-96)